IMVT
Immunovant, Inc.
Healthcare — Biotechnology
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Buy
1.7 / 5
17 analysts
$33.65
$-0.13 (-0.38%)
Target:
$46.00
(36.7%)
Price History
52-Week Range
Sign in to add IMVT to a watchlist or set price alerts.
Fundamentals
| Market Cap | $7.83B |
| P/E Ratio (TTM) | - |
| Forward P/E | -15.65 |
| EPS (TTM) | $-2.77 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -64.82% |
| Debt/Equity | 0.01 |
| Recommendation | Buy 1.7 |
| Analyst Target | $46.00 |
| Analysts | 17 |
| Next Earnings | Aug 6, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 85.7 |
| Beta | 0.79 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $39.28 |
| 52-Week Low | $14.32 |
| 50-Day Avg | $31.78 |
| 200-Day Avg | $25.60 |
| Avg Volume | $1.25M |
| Volume | $1.55M |
Performance Analysis
BULLISHIMVT shows predominantly bullish signals based on its fundamentals and technicals.
+
Showing strength at 77% of its 52-week range.
-
RSI at 85.7 indicates overbought conditions — a pullback may be due.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Buy" from 17 analysts.
+
Average analyst target of $46.00 implies 36.7% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:15 UTC
Back to Screener Export Report